Monday's top analyst calls included AbbVie, AES, AT&T, Boeing, Carnival, CME, Coca-Cola, Comcast, Honeywell, Lululemon Athletica, Netflix, Shopify, Starbucks and Twitter.
With interest rates still at generational lows, investors looking for income from stocks may be in the best place in a while. High-yielding, safer blue chips are available at rock bottom prices.
The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical stocks decreased.
These five companies pay dividends, have shares that are rated Buy, tend to do well when the federal funds rate is cut and make good sense for worried investors now.
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
With billions of dollars flowing in, it has become impossible to ignore the ESG trend. These 15 top ESG stocks appear to be undervalued against the performance of the broader markets.
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and income investors.
24/7 Wall St. has put together a preview of Disney, Ford, Merck, Uber and some of the other most anticipated earnings reports that are expected this week.
The January 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Independent research firm Argus sees better than 25% potential upside for Bristol-Myers Squibb in the coming year.
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
